Shares of Bio-Techne Corp. TECH rose 3.72% to $75.25 Wednesday, on what proved to be an all-around favorable trading session ...

Bio-Techne TECH reported second-quarter fiscal 2025 adjusted earnings per share (EPS) of 42 cents, which exceeded the Zacks ...

Life sciences company Bio-Techne (NASDAQ:TECH) reported Q4 CY2024 results topping the market’s revenue expectations, with ...

Q2 2025 Management View CEO Kim Kelderman highlighted 9% organic revenue growth for the quarter, driven by strong performance in biopharma end markets, particularly large pharma, which benefited GMP ...

RBC Capital analyst Conor McNamara maintained a Hold rating on Bio-Techne (TECH – Research Report) on February 4 and set a price target of ...

Bio-Techne beat second-quarter profit and revenue estimates on Wednesday, helped by growth in its protein sciences unit that makes products to develop therapies ...

Bio-Techne Corp (NASDAQ:TECH) reported stronger-than-expected earnings for the second quarter of fiscal year 2024, with adjusted earnings per share (EPS) of $0.42, surpassing the forecasted $0.39.

Reports Q2 revenue $297.03M, consensus $285.42M. “The Bio-Techne (TECH) team once again executed at a high level and delivered strong second ...

Good morning, and welcome to the Bio-Techne Earnings Conference Call for the Second Quarter of Fiscal Year 2025. At this time, all participants have been placed in a listen-only mode and the call will ...

Shares of Bio-Techne Co. (NASDAQ:TECH – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the stock, Marketbeat ...

The firm's Protein Sciences segment saw revenues increase 7 percent, while the Diagnostics and Spatial Biology segment's revenues rose 12 percent.

Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ending December 31, ...